Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cytokinetics ( (CYTK) ) has issued an update.
On February 10, 2025, Cytokinetics, Incorporated appointed Robert E. Landry to its Board of Directors as a Class II member, with an initial term until the 2027 annual stockholders meeting. Landry was also appointed to the Audit Committee, and he will participate in the company’s non-employee director compensation arrangements, which include annual retainers and equity grants. This appointment aligns with Cytokinetics’ governance policies, as Landry is considered independent under relevant guidelines and requirements.
More about Cytokinetics
Cytokinetics, Incorporated operates in the biopharmaceutical industry, focusing on discovering, developing, and commercializing innovative muscle biology-driven therapeutics. The company primarily targets diseases that impair muscle function, aiming to address unmet medical needs in areas such as heart failure and amyotrophic lateral sclerosis (ALS).
YTD Price Performance: -13.73%
Average Trading Volume: 1,310,601
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $5.05B
See more data about CYTK stock on TipRanks’ Stock Analysis page.
